



**S5 Fig.** Kaplan-Meier survival curves for first-line progression-free survival (PFS) (A), total PFS (B), and cancer-specific survival (CSS) (C) for patients treated with mammalian target of rapamycin inhibitor as first-line treatment in metastatic non-clear cell renal cell carcinoma according to the Memorial Sloan Kettering Cancer Center risk model.